Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14829208 | 0.77 | NQO2 (0.32) | HRH4HRH3SMN1; SMN2 | |
| SCHEMBL14829014 | 0.76 | HRH4 (0.53) | HRH4HRH3SMN1; SMN2 | |
| SCHEMBL26684980 | 0.72 | — | — | |
| SCHEMBL20704188 | 0.70 | CHRNB2 (0.32) | — | |
| SCHEMBL16913805 | 0.69 | PIK3C3 (0.35) | KMT2A | |
| SCHEMBL30600932 | 0.69 | MAPK1 (0.33) | — | |
| SCHEMBL1366474 | 0.69 | MAPK1 (0.33) | — | |
| SCHEMBL13202779 | 0.69 | — | — | |
| SCHEMBL31586523 | 0.69 | — | — | |
| SCHEMBL31229804 | 0.69 | CHRNB2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| EP-3461825-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2019-04-03 | — | — | EP | disclosed |
| EP-2760865-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RES LAB (KR) | 2018-07-11 | — | — | EP | disclosed |
| US-9586959-B2 | Substituted tricyclic heterocycles as histamine 4 receptor inhibitors | C&C RESEARCH LABORATORIES (KR) | 2017-03-07 | — | — | US | disclosed |
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2014-10-23 | — | — | US | disclosed |
| EP-2760865-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013048214-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CDK1, CSNK1A1, CSNK1G1 | POLB 2109/4885GAA 2622/4885KMT2A 716/4885 |
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | HRH4, HRH2, HRH1 | POLB 4222/4885GAA 4469/4885KMT2A 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.